"Health News - Medicine, Diet and Fitness"

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

The U.S. Food and Drug Administration (FDA) has given priority review status to the drug Abilify which is manufactured by Bristol-Myers Squibb and Otsuka Pharmaceutical.

(more…)

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

The U.S. Food and Drug Administration (FDA) has given priority review status to the drug Abilify which is manufactured by Bristol-Myers Squibb and Otsuka Pharmaceutical.

(more…)

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

The U.S. Food and Drug Administration (FDA) has given priority review status to the drug Abilify which is manufactured by Bristol-Myers Squibb and Otsuka Pharmaceutical.

(more…)

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

The U.S. Food and Drug Administration (FDA) has given priority review status to the drug Abilify which is manufactured by Bristol-Myers Squibb and Otsuka Pharmaceutical.

(more…)

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

The U.S. Food and Drug Administration (FDA) has given priority review status to the drug Abilify which is manufactured by Bristol-Myers Squibb and Otsuka Pharmaceutical.

(more…)

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

The U.S. Food and Drug Administration (FDA) has given priority review status to the drug Abilify which is manufactured by Bristol-Myers Squibb and Otsuka Pharmaceutical.

(more…)

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

The U.S. Food and Drug Administration (FDA) has given priority review status to the drug Abilify which is manufactured by Bristol-Myers Squibb and Otsuka Pharmaceutical.

(more…)

BBC reports that “a study published in the Public Library of Science journal by researchers from the Harvard School of Public Health suggests the policy has saved Brazil around $1bn between 2001 and 2005.”  The article itself is available freely online as a part of  the open access policy of PLoS.

(more…)

Thirteen states this year have seen legislative proposals aimed at limiting financial relationships between physicians and drugmakers. Most bills failed to pass, due to heavy pressure from pharmaceutical lobbyists, experts said, but new efforts are afoot.

The latest proposals include a Michigan bill that would make that state the second in the nation after Minnesota to place a limit — $100 — on the total value of gifts a drugmaker can give a physician in a year. Michigan and Massachusetts are considering so-called sunshine laws requiring drug companies to publicly disclose any gifts, payments, subsidies or incentives worth more than $25.

(more…)

A new study shows that alcohol dependency, major depression, and social phobia are widespread in the U.S. workforce, HealthScout News reported July 29.

According to the report, 25 percent of American workers experiences at least one mental or addictive disorder each year.

“The rates are extremely high,” said Robin Hertz, study author and a senior director of population studies at Pfizer Pharmaceuticals Group, which paid for the research. “As a nation, we have to be more attentive to these types of problems. There is a mythology out there that if you are at work you are healthy. That is not really true.”

(more…)